Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.65 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22703743 | 1.00 | CRBN (0.73) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL5958854 | 1.00 | CRBN (0.73) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL18270971 | 0.93 | CRBN (0.63) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL19451224 | 0.90 | CRBN (0.73) | CRBNCSNK1A1 | |
| SCHEMBL22703748 | 0.90 | CRBN (0.73) | CRBNCSNK1A1 | |
| SCHEMBL22703755 | 0.90 | CRBN (0.73) | CRBNCSNK1A1 | |
| SCHEMBL24833121 | 0.89 | CRBN (0.58) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL22564891 | 0.88 | CRBN (0.57) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL26021396 | 0.88 | CRBN (0.57) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL25989601 | 0.88 | CRBN (0.57) | CRBNCSNK1A1IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088245-A1 | DEGRADATION AGENT AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2022120355-A1 | TEAD DEGRADERS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022047145-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021222114-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020233512-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | 成都海创药业有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885CSNK1A1 211/4885IKZF2 361/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885CSNK1A1 211/4885IKZF2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.